Featured Research

from universities, journals, and other organizations

Molecular Mechanisms In Multiple Myeloma Illluminated: Could Lead To More Effective Therapies

Date:
August 17, 2007
Source:
Cell Press
Summary:
Two new studies may lead to the development of more effective therapies for individuals with multiple myeloma, a common and incurable blood cell cancer. The research provides new insight into the molecular mechanisms that underlie aberrant NF-B activity in muliple myeloma tumor cells and underscores the relevance of the signaling pathway as a target for MM therapy.

Two new studies may lead to the development of more effective therapies for individuals with multiple myeloma (MM), a common and incurable blood cell cancer. The research, published by Cell Press in the August issue of the journal Cancer Cell, provides new insight into the molecular mechanisms that underlie aberrant NF-B activity in MM tumor cells and underscores the relevance of the NF-B signaling pathway as a target for MM therapy.

MM is a cancer of the plasma cell, a blood cell that produces antibodies to help the body fight off infections. Previous research implicates abnormal activation of the NF-B signaling pathway as a key event in MM pathology. NF-B target genes are known to be involved in cell proliferation and cell survival. Although there is significant overlap and interplay between them, there are two separate pathways that lead to activation of NF-B, the classical pathway and the alternative pathway.

Constitutive activation of NF-B to block apoptosis has been implicated in various types of cancer, but the molecular mechanisms involved are not well understood. Two separate research groups used a variety of sophisticated genomic techniques to examine mutations in hundreds of MM patient samples and cell lines to identify mutations that impact NF-B activation.

Dr. Louis M. Staudt from the National Cancer Institute led a research group who revealed the importance of both the classical and alternative NF-B pathways in MM pathogenesis. Most MM patient samples examined exhibited NF-B pathway activation via diverse genetic abnormalities. Importantly, targeted disruption of the classical NF-B signaling blocked myeloma proliferation and induced cell death. "These genetic and functional data provide a molecular framework for the rational development of NF-B pathway inhibitors for the therapy of MM," offers Dr. Staudt.

In a separate study, Dr. Rafael Fonseca, from the Mayo Clinic Arizona, and colleagues report mutations in several genes that result in constitutive activation of the alternative NF-B pathway. "We propose that the acquisition of the mutations identified in our study results in the accumulation of malignant plasma cells beyond the physiological control of the bone marrow compartment. Our results suggest a mechanism by which MM cells can overcome these limitations through acquisition of mutations that result in constitutive and ligand-independent activation of the alternative NF-B pathway," explains Dr. Fonseca.

Taken together, results for these studies define diverse mutations that lead to pathological activation of NF-B signaling in MM and describe a shift of plasma cells from dependence on the microenvironment to an environment-independent state during progression of MM. Regardless of the specific method of activation, the NF-B pathway plays a central role in MM pathogenesis and is an excellent target for development of new therapeutics.

These articles are accompanied by a preview article written by Dr. Thomas D. Gilmore from Boston University.

Article 1: Annunziata et al.: "Frequent Engagement of the Classical and Alternative NF-B Pathways by Diverse Genetic Abnormalities in Multiple Myeloma." Publishing in Cancer Cell 12, 115--130, August 2007, DOI 10.1016/j.ccr.2007.07.004.

The researchers include Christina M. Annunziata, R. Eric Davis, Yulia Demchenko, Ana Gabrea, Georg Lenz, George Wright, Sandeep Dave, Elaine M. Hurt, Bruce Tan, Hong Zhao, W. Michael Kuehl, and Louis M. Staudt of the National Cancer Institute, Bethesda, MD; William Bellamy, Fenghuang Zhan, Ichiro Hanamura, Owen Stephens, Madhumita Santra, David R. Williams, Bart Barlogie, and John D. Shaughnessy, Jr. of the University of Arkansas for Medical Sciences, Little Rock, AR; Wenming Xiao of the National Institutes of Health, Bethesda, MD; Lenny Dang of Millennium Pharmaceuticals, Cambridge, MA.

This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research (L.M.S., W.M.K.); NIH grant CA55819 (B.B. and J.D.S.); and the Lebow Fund for the Cure (J.D.S.).

Article 2: Keats et al.: "Promiscuous Mutations Activate the Noncanonical NF-B Pathway in Multiple Myeloma." Publishing in Cancer Cell 12, 131--144, August 2007, DOI 10.1016/j.ccr.2007.07.003.

The researchers include Jonathan J. Keats, Rafael Fonseca, Marta Chesi, Roelandt Schop, Wee-Joo Chng, Scott Van Wier, Rodger Tiedemann, Chang-Xin Shi, Michael Sebag, Esteban Braggio, Travis Henry, Yuan-Xiao Zhu, Homer Fogle, Gregory Ahmann, Riccardo Valdez, A. Keith Stewart, and P. Leif Bergsagel of Mayo Clinic Arizona, Scottsdale, AZ; Tammy Price-Troska, Shaji Kumar, Philip Greipp, and Angela Dispenzieri of Mayo Clinic, Rochester, MN; Angela Baker, Catherine Mancini, Michael Barrett, Jeff Trent, and John Carpten of Translational Genomics, Phoenix, AZ; Leslie A. Brents of National Cancer Institute, Bethesda, MD; Barb Bryant and George Mulligan of Millennium Pharmaceuticals, Cambridge, MA; Laurakay Bruhn of Agilent Technologies, Santa Clara, CA.

This work was supported by grants from the National Cancer Institute, and the Donaldson Charitable Trust Fund (R.F.).


Story Source:

The above story is based on materials provided by Cell Press. Note: Materials may be edited for content and length.


Cite This Page:

Cell Press. "Molecular Mechanisms In Multiple Myeloma Illluminated: Could Lead To More Effective Therapies." ScienceDaily. ScienceDaily, 17 August 2007. <www.sciencedaily.com/releases/2007/08/070813121034.htm>.
Cell Press. (2007, August 17). Molecular Mechanisms In Multiple Myeloma Illluminated: Could Lead To More Effective Therapies. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2007/08/070813121034.htm
Cell Press. "Molecular Mechanisms In Multiple Myeloma Illluminated: Could Lead To More Effective Therapies." ScienceDaily. www.sciencedaily.com/releases/2007/08/070813121034.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins